Format

Send to

Choose Destination
Cancer Chemother Pharmacol. 2009 Oct;64(5):1053-8. doi: 10.1007/s00280-009-1063-0. Epub 2009 Jul 12.

A sphingosine kinase inhibitor induces cell death in temozolomide resistant glioblastoma cells.

Author information

1
Department of Pathology, Duke University Medical Center, Durham, NC, USA. meryem_bektas@med.unc.edu

Abstract

PURPOSE:

Sphingosine kinase is an oncogene that is up-regulated in several solid tumors. The product of the sphingosine kinase activity, sphingosine-1-phosphate is a potent mitogen involved in diverse cell processes such as cell survival and migration. Current standard therapy in the treatment of glioblastoma multiforme (GBM) is a combination of surgery, radiation, and chemotherapy using the drug temozolomide (TMZ). However, virtually all tumors become resistant to TMZ. Therefore, new drug targets are necessary. In this study, we investigated whether inhibiting sphingosine kinase could induce cell death in TMZ-resistant GBM cells.

METHODS:

To study TMZ resistance in vitro, we have generated TMZ-resistant cell lines from established GBM cells. We used a potent inhibitor of sphingosine kinase to study its effect on colony formation and cell growth in GBM cells with a limited dilution and WST assay. Moreover, cell death was determined by measuring caspase-3 activity using flow cytometry.

RESULTS:

A sphingosine kinase inhibitor reduced cell colony formation and activated caspase-3 in both TMZ-sensitive and resistant GBM cells.

CONCLUSION:

Addition of a sphingosine kinase inhibitor to the standard chemotherapy regimen against GBM may be beneficial.

PMID:
19597728
PMCID:
PMC3674501
DOI:
10.1007/s00280-009-1063-0
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center